No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 20 of the 38 quarters in the window, leaving 18 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 39
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T20:59:14.513Z. Latest historical point 2025-06-27. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Exicure, Inc. (XCUR) stock was $1.08 as of Oct 6, 2026, 4:00 PM EDT, up 0.93% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -74.2% · 3-year avg -32.3%/yr · 5-year avg -64.1%/yr
Exicure, Inc. does not have significant operations.
Biotechnology · Redwood City, CA
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-18.60
Revenue Est.
$1.64M
Last Quarter Results
EPS
$-8.30
vs Estimate
$-6.00
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1XCUR | $6.88M | $1.08 | +0.93% | -74.17% | -64.13% | N/A | N/A |
| 2BOLT | $6.74M | $3.51 | +0.31% | -33.96% | -57.61% | N/A | vs XCUR |
| 3KALA | $7.04M | $0.36 | +0.41% | -99.52% | -85.73% | N/A | vs XCUR |
| 4CURX | $7.07M | $4.99 | +0.60% | -68.03% | N/A | N/A | vs XCUR |
| 5SKYE | $7.12M | $1.62 | -6.36% | -95.38% | -60.42% | -46.85% | vs XCUR |
| 6LGVN | $7.15M | $2.35 | -6.37% | -67.97% | -62.60% | N/A | vs XCUR |
N/A
$0.00
vs Estimate
$1.64M
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$1.08
High
N/A
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-18.60 | $-18.60 | $-18.60 | 1 |
| Quarter ending Dec 2026 | $-21.00 | $-21.00 | $-21.00 | 1 |
| Quarter ending Mar 2027 | $-13.88 | $-13.88 | $-13.88 | 1 |
| Quarter ending Jun 2027 | $-21.00 | $-21.00 | $-21.00 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $1.64M | $1.64M | $1.64M | 1 |
| Quarter ending Dec 2026 | $1.55M | $1.55M | $1.55M | 1 |
| Quarter ending Mar 2027 | $6.99M | $6.99M | $6.99M | 1 |
| Quarter ending Jun 2027 | $3.50M | $3.50M | $3.50M | 1 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
